We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Malaria is an infectious disease caused by the parasitic protozoan Plasmodium.
It is transmitted through the bite of mosquitoes of the genus Anopheles. The mosquito acts as a vector or transmitter of the disease. The mosquito bites an already infected person. The parasite reproduces and develops inside the mosquito. The mosquito subsequently bites another person who in turn becomes infected.
It cannot be transmitted from one person to another without the presence of a mosquito, except in the case of an infected blood transfusion or from mother to foetus through the placenta.
Mosquitoes generally bite during hours of low light: dusk, during the night and dawn. They live in urban as well as rural areas. During the rainy season there are more mosquitoes, therefore the risk of being bitten and contracting the disease is higher.
Malaria was eradicated in Europe over 50 years ago, and so cases seen are due to travel to endemic countries for reasons such as immigration, tourism, and business. The majority of cases are seen in immigrants after having returned to their native countries to visit family. This occurs due to the fact that although they should be taking the same measures as tourists, more often than not they do not. 95% of cases are imported from Africa, 3% from Asia and 1% from South America.
The incubation period varies from one week to over a month. As such, symptoms may present themselves shortly after entering an endemic area or several months after having returned from one.
Symptoms generally include high fever, chills, headache, sweating, and generalised joint and muscle pain. Some patients experience symptoms every 2-3 days and others experience a persistent fever. If the disease is not diagnosed and treated accordingly it can develop rapidly and become life-threatening. Alterations in consciousness, convulsions, coma, difficulty breathing and haemorrhaging are signs of a bad prognosis. Requires immediate medical attention.
It is important to keep in mind that any child with a fever and history of travel to an endemic country should be suspected of having malaria unless proved otherwise.
Malaria is common in tropical and subtropical areas (both sides of the equator). The countries in which malaria is endemic have been grouped into 4 regions: Africa, America, Asia and the Pacific, and the Middle East and Eurasia. More than 90% of the malaria cases in Africa are caused by Plasmodium falciparum, the most serious and deadly. America and the Middle East and Eurasia are dominated by Plasmodium vivax. A much more common form of malaria with a lower mortality rate.
In Asia and the Pacific, infections are a mix of Pl. vivax and Pl. falciparum with a moderate number of cases of mortality. Generally speaking, the areas with the highest risk for travellers are Sub-Saharan Africa, South East Asia, Papua New Guinea and the Indian subcontinent.
A diagnosis is reached through detection of the parasite either in the red blood cells, or through processes of molecular biology.
Early diagnosis is crucial. The pharmaceuticals used in Europe differ from those used in endemic countries in places like Africa. Depending on the severity, certain intravenous drugs may be required immediately. Severe malaria is usually treated in Intensive Care Units in anticipation of serious complications.
In a case of suspected malaria, blood testing is crucial. If there are alterations in any organs, individual exploration of said organs is necessary; for example, brain image scanning in the event of nervous system impairment, which is very common in severe cases of malaria.
With malaria, prevention is crucial. The use of antimalarial medication before travelling to endemic countries is vital, as failure to do so means the probability of contracting the disease is very high due to the fact that it is almost impossible to avoid mosquito bites even by using insect repellent and mosquito nets.
Antimalarial medication, to be prescribed by a doctor in each case, should be started before beginning a trip up until a few days after returning.
Minority diseases, also called rare diseases, are those that affect between 5% and 7% of the population. They are very varied, affecting different parts of the body with a wide range of symptoms that change both between diseases and within the same disease. It is estimated that some 30 million people in the EU, 3 million in Spain, and around 350,000 in Catalonia suffer from one.
The complexity of most rare diseases requires multidisciplinary care with professionals from different medical specialities, case management for nursing, psychological support and also social work.
The Vall d'Hebron Barcelona Hospital Campus is home to more than 100 specialist professionals dedicated to the care of more than 2,000 rare diseases. Apart from treating the most rare diseases of any centre in Spain, it is one of the leading hospitals in Europe in this field. In fact, Vall d'Hebron is part of 20 European reference networks, known as ERN. This makes this hospital a highly specialised centre for rare diseases, from birth to adulthood, through a networked system that allows sharing of resources and knowledge with other world-class hospitals.
Adult and child
Pediatric
This concentration of patients with rare diseases at Vall d'Hebron improves knowledge and promotes research. Research in this field focuses above all on improving diagnostic capacity for diseases that are often difficult to diagnose and on developing new treatments for those diseases. In the case of diseases with few patients, publicly funded research is often the main avenue for the discovery of new drugs, and public health is the framework that provides the public with access to high medication complexity.
For more information, contact the Rare Disease Team at the following email address: minoritaries@vallhebron.cat
The Physical Medicine and Rehabilitation Department offers comprehensive. multidisciplinary treatment for patients, with the aim of achieving the highest level of autonomy, functional capacity and quality of life, using therapeutic measures and technical support aimed at correcting or minimising the disability diagnosed.
Ours is a transversal department, meaning we collaborate with many other medical and surgical departments at the Hospital. Our ability to provide support in all healthcare areas guarantees coordinated care for patients throughout their stay. We are a reference centre in Catalonia for various highly complex processes (spinal cord injury, acquired brain damage, spina bifida, burns) and we also engage in teaching and research.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.